MetLife Investment Management’s Third Harmonic Bio THRD Stock Holding History

MetLife Investment Management’s Portfolio THRD Stock Details THRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-16,859	Closed	-$90.7K	–	2872
2025 Q3	$90.7K	Hold	16,859	–	–	﹤0.01%	2691
2025 Q2	$91.5K	Buy	+16,859	New	+$84.1K	﹤0.01%	2593
2025 Q1	–	Sell	-12,859	Closed	-$132K	–	2824
2024 Q4	$132K	Hold	12,859	–	–	﹤0.01%	2499
2024 Q3	$174K	Hold	12,859	–	–	﹤0.01%	2357
2024 Q2	$167K	Buy	12,859 +1,255	+11%	+$15.5K	﹤0.01%	2355
2024 Q1	$110K	Hold	11,604	–	–	﹤0.01%	2490
2023 Q4	$127K	Hold	11,604	–	–	﹤0.01%	2487
2023 Q3	$74.2K	Buy	+11,604	New	+$70.9K	﹤0.01%	2734

Other funds holding THRD

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

MetLife Investment Management's THRD Position: Q4 2025 in Review

MetLife Investment Management sold out of Third Harmonic Bio (THRD) in Q4 2025, closing a stake of 16,859 shares — an estimated $90.7K sold.

MetLife Investment Management first reported a position in THRD in Q3 2023 and held it in 8 quarters. The position peaked at $174K in Q3 2024. 4 funds tracked by Wall St. Rank hold THRD as of Q4 2025.

MetLife Investment Management reported no remaining Third Harmonic Bio position as of Q4 2025 after selling out during the quarter.
MetLife Investment Management sold 16,859 Third Harmonic Bio shares in Q4 2025, an estimated $90.7K.
MetLife Investment Management first reported a position in Third Harmonic Bio in Q3 2023 and held it in 8 quarters.
MetLife Investment Management's Third Harmonic Bio position peaked at $174K in Q3 2024.
4 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q4 2025.

Based on MetLife Investment Management's 13F filing for Q4 2025, filed 12 Feb 2026.